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0. Radostits: Perhaps I can pose a question related to 
why we came here. Do we have sufficient evidence to 
show that the use of fluoroquinolones in poultry has 
an effect on Cumpylobacter, and what is the potential 
human health hazard? 
E. Gonder: Is the resistance transferred to humans? This 
is what we do not know. 
0. Radostits: My interest in this topic goes back a long 
way, almost to the Swann Report, and I have been 
following the literature since then. My specific interest 
is the potential of transference of resistance in beef 
cattle pathogens to humans, because we use antibiotics 
in beef cattle practice, beef cattle health, and production 
management. I think that there are eight or nine theo- 
retical steps from the presence of the organism in the 
animals, to the use of the antibiotics and the emergence 
of resistance and slaughtering of the cattle. Beef is not 
sterile when it is fresh; are the organisms transferable to 
humans working on the farm, in the factory plant, in the 
retail stores, and at the consumer level, and does that 
organism colonize those humans? Does it cause disease 
in those humans? Is it difficult to treat? I have been 
playing around with a model. I am not a statistician, nor 
a mathematician, and am trying to estimate the pro- 
babilities in each one of those steps and multiply them. 
Question: What evidence do we have that this link exists 
between the use of jluoroquinolones in poultry and the 
subsequent dire consequences in humans? Will we ever 
be able to reconstruct that? I think that Dr Wassenaar 
mentioned in her paper that Endtz from Holland says it 
would be impossible to reconstruct that link. 
T. Wassenaar: If you had good genotyping evidence 
that it did actually occur, you should be able to follow 
bad bugs from chicken to people, if you could fingerprint 
them. My own analysis, which doesn’t have the luxury of 
following individual campylobacters or strains, suggests 
to me that if chickens are not significantly or detectably 
carrying Campylobacter to people, which the home data 
suggest to me, then probably they aren’t carrying fluoro- 
quinolone-resistant campylobacters either. That is just a 
commonsense step, and I know that common sense has 
notoriously misled people before. I think it is common 
sense that if you look at chickens, you see Campylo- 
batter. Some percentage will survive to infect people, 
and some people will get sick because of it, but I don’t 
find a shred of evidence that this actually happens. 
M. Ginevan: One thing we can do is to construct positive 
models, to see, first, what they tell us, and second, what 
the data gaps are. The one thing that I don’t think we will 
be able to do, certainly with the available data, is to tell 
whether or not these models represent truth or any close 
approximation to it. I don’t think we are there yet. 
I don’t hear people saying that we know this. I hear 
people saying that we hear this but it doesn’t bear 
scrutiny, and that what we know isn’t what we would like 
to know. I think the key is to try to develop models, and 
iterate the development of the models to the point 
where we have put a lot of factors aside. Is the use of 
fluoroquinolones in poultry a clear and present danger 
in terms of Campylobacter resistance? There doesn’t 
seem to be any evidence to that effect. As Tony pointed 
out, the signs in the regression equation are wrong. I 
think there are many other things out there which we 
need to look at before we can have any confidence that 
we know what is going on. 
G. Tillotson: Something to keep in mind about fluoro- 
quinolone resistance is that it is not a transferable 
resistance, as we see with other antibiotics. It is a 
point mutation in an individual bacterium, and only 
its daughters are going to remain resistant. It is not 
transferable as with tetracycline, where resistance can be 
transferred from Campylobacter to E. coli. 
T. Wassenaar: That remains to be proven, because why 
could not a point mutation transform from one strain 
to another? The wheel doesn’t have to be reinvented. 
Successful genes are spreading by transfer within the 
species, but not every episode of fluoroquinolone resist- 
ance arises from a spontaneous point mutation. We 
don’t know to what extent already existing genes are 
spreading by transformation. 
Question: Is there any evidence to show that there is 
transferable resistance? 
T. Wassenaar: For the GYR A gene, it has not been 
shown yet. It is not a difficult experiment to do, and 
would predict that it will happen, but whether it will 
happen outside a host gut, which is when mixing of 
strains that are not resistant occurs, is a different question. 
C. Thornsberry: It is not that simple. There has been one 
legitimate report of plasmid-mediated fluoroquinolone 
resistance, but to get real clinical resistance in these 
organisms, there would have to be more than one 
mutation. Clearly, they could be transformed. The real 
problem here is not horizontal transfer between the 
bugs, but horizontal transfer between the animals and 
the humans. The question that we need to answer is, if 
we look at this whole business in total with fluoro- 
quinolones, issues have been made with E. coli, but 
I don’t think that E. coli is a problem at all with 
fluoroquinolone resistance. I think that the 3% or 4% 
resistance that we find in humans is a matter of infection 
control. I think that Cumpylobacter is a different story. 
It seems clear to me that this is one of the cases where, 
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without doubt, Campylobacter will become resistant to 
fluoroquinolones. If we want to follow up on Campylo- 
batter and know the real reason, that is the question we 
need to answer. Why are these organisms so much more 
likely to become resistant than other organisms that we 
see in the gut? 
Comment: I have a few comments on that. One is that 
I think there are different degrees of resistance. There 
is something that puzzles me, and I would be delighted 
if somebody here knows the answer. There was an 
abstract by Laura Piddock years ago, reporting that 
about 39 of 40 people with resistant isolates responded 
to treatment with fluoroquinolones, and I have never 
known what that abstract meant. On the face of it, it 
sounds like what is resistant in a Petri dish may not be 
clinically resistant. 
G. Tillotson: This could be the case, but I would have to 
ask Laura to be sure. At one point in time, I think it was 
the public health laboratory that was defining resistance 
as something quite different from what we normally 
consider it to be. They were saying that if the MIC is 
above 0.1 mg/L it is resistant, and this might be what 
Laura was talking about. 
P. Fedorka-Cray: Maybe I can add to that. Even the 
CDC case-control study, which used the 4 mg/mL break- 
point, showed that resistant infections responded to 
treatment. We need to call into question what the 
definition of resistance is in all these studies; it is not an 
NCCLS-established breakpoint. 
G. Tillotson: I think their point was not that they were 
calling these clinically resistant, but that there was in- 
creasing creeping resistance. I think that is a legitimate 
thing to do, but the terms clinically susceptible and 
clinically resistant should not be used. 
R. Camevale: The other big issue that we started to 
discuss was the theoretical possibility of transfer. 
Previously CVM predicted resistance emergence once we 
introduced enrofloxacin. Resistance among human 
isolates of Campylobacter has allegedly increased since 
1996, and it may be related to the consumption of 
enrofloxacin treated chickens. When I look at the data, 
I don’t see evidence that this is true. There is much 
evidence that the reality is quite different, which I think is 
exciting and which I would like to pursue. I would be very 
curious whether anybody else has obtained data that 
confirms this. Is the simple story that CVM told correct? 
When I look at the data and come up with ideas, I live in 
perpetual fear of being considered eccentric. 
0. Radostits: Could I ask Clyde to comment on the 
statement you made that fluoroquinolone resistance is 
inevitable? What are the potential consequences of that 
happening in the context of this symposium today? 
C. Thornsberry: That wasn’t quite what I said. What 
I said was that, compared to E. coli, resistance to a 
fluoroquinolone is much more likely to develop in a 
campylobacter, I don’t know the reason for that. 
T. Wassenaar: One of the reasons may be that 
Campylobacter can become resistant through a one- 
point mutation. Another thing is that the cost of being 
resistant for a campylobacter is probably very low, and 
this has severe consequences. If we were to remove the 
selective pressure caused by the antibiotic, it might not 
lead to much change in the population at shorter or 
even medium periods of time. In other words it doesn’t 
matter to the organism whether it has the mutation 
GyrA or not; it will grow equally well. Even if the 
selective pressure is removed, the problem will not be 
solved. 
D. Newell: I am not sure that this is necessarily true; 1% 
of flocks in the USA are being treated with fluoro- 
quinolones, but we are not seeing a huge number of 
fluoroquinolone-resistant campylobacters, and I think 
that there is a cost for a gyrase mutation. We just don’t 
know what it is at the moment, and studies are urgently 
needed in this area. 
G. Tillotson: I would like to add something to what Tony 
Cox was asking before. Fluoroquinolone resistance is 
supposedly growing on a daily basis, and we are actually 
seeing a lot more chicken consumption in this country. 
From what I understand, it has increased by 25-33% in 
the last 2-3 years. That in itself should also be leading 
to an increase in the incidence of Campylobacter in- 
fections, and also the fluoroquinolone resistance. This is 
a very complex story, and we don’t have definite answers. 
D. Meeker: I have a question on the quantitative aspects 
of poultry fluoroquinolone use and the presence of 
resistant organisms. If the drug is being used in fewer 
than 1% of the chicken houses at any one point in time, 
I don’t understand how there can be a lo-fold or X-fold 
leap in the incidence of resistant organisms, unless, at the 
processing stage, there was successful persistence of 
these organisms that were never cleaned out from shift 
to shift or day to day. It seems that, on a micro-scale, by 
following one cohort of treated birds through their state 
of processing and seeing what happens to that pro- 
duction house with the next cycle or the next cycle when 
antibiotic was not being administered, you would get a 
sense of how persistent the blip is coming from that one 
source and that one processing plant. To me, it seems 
that this question could be addressed. 
C. Hofacre: That is the exact same question that poultry 
veterinarians have asked; if the resistance was due to our 
use of enrofloxacin, and such a small amount was used, 
why is the level rising at the rate that the CDC says that 
it is rising? 
M. Ginevan: Has anyone related it to air travel? 
T. Cox: This is a useful thing to look at, and, actually, 
if foreign travel is subtracted out, it is my impression 
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that the Cumpylobacter fluoroquinolone resistance rate 
in the USA has not been increasing. I therefore think 
that travel is a significant factor. 
M. Kist: I have an example from the European coun- 
tries. If it is true that this incidence of fluoroquinolone- 
resistant Campylobacter strains in humans results from 
eating poultry, then it is difficult to understand why, for 
example, in the UK 12% of strains isolated from poultry 
are resistant, and in Spain 100% are resistant. Also, if 
we look at the figures for resistance in humans, we see 
resistance rates of about 15% in the UK for human 
strains, but 80% in Spain. I don’t think that there 
are large differences in the use of fluoroquinolones in 
poultry flocks between Spain and the UK. There must 
be other factors leading to these different levels of 
resistance in different countries. One of these could be 
the use of fluoroquinolones in human medicine. To my 
knowledge, fluoroquinolones are used more extensively 
in Spain for the treatment of human infections in com- 
parison to other countries. They are also used prophy- 
lactically in Spain. 
D. Newell: Is it not also true that travelers who leave 
the USA use ciprofloxacin prophylactically if they go to 
Asia or Mexico? 
M. Pasternack: Yes. 
D. Newell: So, all those travel-related campylobacters 
have to be resistant. 
C. Thornsberry: Travellers may not be the only source. In 
the USA, about $1 billion worth of ciprofloxacin is used 
every year, and about $1 billion worth of levofloxacin, 
plus ofloxacin and other drugs. If you try to base resist- 
ance on the usage of drugs, you really have to stretch a 
point. There are essentially no data supporting the idea 
that drug usage causes resistance. I get frustrated when I 
am reviewing manuscripts.The writers make these claims, 
but don’t supply any references. I am not sure how much 
effect the use of drugs has on the development of 
resistance. I think that what we need to do is to match the 
drug and the bug. With fluoroquinolones, Campylobacter 
is one of those bugs that does become resistant, but from 
what you were talking about today, given the right 
conditions, it grows rapidly. Maybe some selective 
pressure is created. I think that there is more to consider 
here than the amount of drug that we use. 
Another point that we should make is that anti- 
biotics don’t cause resistance, but select resistant strains; 
this is not always realized by the community. 
R. Carnevale: Is there any scientific evidence that the 
use of fluoroquinolones in poultry has any beneficial 
effect on human populations, by providing more whole- 
some or cleaner food? 
M. Ginevan: That is an interesting question, and the 
answer depends on who you ask. According to the 
USDA data, the incidence of salmonellosis in inspected 
poultry has been dropping over the last several years. 
This may or may not be connected with fluoroquinolone 
usage; hopefully, it has more to do with the HACCP 
program, but this is going to be difficult to evaluate, 
because the situation is not very static. The inspection 
systems and the processing procedures keep changing. 
E. Gander: I have heard it said that the use of 
enrofloxacin strengthens the intestine of birds. I have 
also heard it said that enrofloxacin weakens the intestine 
of birds, and that unhealthy birds that go to market may 
be smaller than average, and more likely to be cut up 
in the process and to spray their fecal contents and 
gut matter around the processing plant. If some of this 
is true, and if the ban on enrofloxacin would lead to 
smaller birds that are not calibrated with respect to 
current equipment, and if chickens are the problem, 
which is a key ‘if’, I can see how a higher microbial load 
might reach the consumer. However, I have not seen any 
data to indicate whether this is true or false. 
C. Hofacre: It is difficult for me to comment on that, 
except anecdotally. I think it would be reasonably safe 
to say that if you have sick birds and you send them into 
the processing plant, generally the intestines tend to be 
somewhat more fragile, and you experience more fecal 
contamination during the entire procedure, leading to 
an increased risk. If you have a flock of birds which is 
sick for almost any reason, and the sickness begins to 
affect the growth rate, this does not occur uniformly 
within the flock. Consequently, the uniformity of the 
flock decreases with respect to whether they are sick 
and treated or sick and not treated. This has a negative 
impact, particularly on chicken plants where a high 
proportion of the equipment is highly automated and 
they are operating under very tight size criteria. This is 
less of a problem for turkey plants, where we can 
tolerate more changes and differences in size, and 
where the procedure is considerably less automated. 
T. Cox: I haven’t seen any studies connecting gut fragility 
with fluoroquinolone use or non-use. However, I have 
seen studies that have associated feed-grade antibiotics 
to prevent necrotic enteritis with a healthier gut that 
does not rupture during slaughter. The major use of 
fluoroquinolones in poultry is probably not going to be 
for intestinal disease. 
D. Newall: Does anybody have any data on the in- 
cidence of fluoroquinolone resistance in organically kept 
birds that are not themselves treated? 
T. Cox: I have tangentially relevant data, from Effler’s 
data set from Hawaii. It turns out that, in some subsets, 
there is a variable called organic prod, which is organic 
produce, but it does not comprise chickens. This appears 
to be a risk factor for campylobacteriosis. 
D. Meeker: There was an article some years ago describing 
fluoroquinolone-resistant bacteria in bustards in Saudi 
Arabia. 
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R. Carnevale: I would like to get this group to give some 
sort of view on this. I have been looking at this issue for 
some years now, and I don’t think that anyone can argue 
that the data are clear-cut one way or the other. Clearly, 
using antibiotics selects for resistance. Clearly, people 
can get Cumpylobacter infections from a number of 
sources, and poultry probably comprises one of these, 
The question is, what is the real level of risk? This is 
really what we are dealing with here. We are not dealing 
with theoretical arguments about whether it can happen, 
but with arguments about what is the significance of that 
risk, and what is the significance of the potential transfer 
of these resistant bacteria, because we have to consider 
the remedies being proposed, both by activist groups 
and by government agencies; that is, total and 
unequivocal bans. These are products, in the case of 
fluoroquinolones in this country at least, that are highly 
regulated, prescription-only drugs. They are restricted to 
veterinary use for therapeutic use only, but it seems to 
me that the question is whether the data justify taking 
the kind of risk management approach that is being 
suggested, which is complete elimination, as opposed to 
more judicious use, which is already being practiced. The 
level of use in the USA is maybe 1% of flocks, and I 
think that we need to get some opinions on whether the 
risk is high enough to justify what is being proposed. In 
my opinion, it is not; but then again, we are operating in 
an arena of zero-risk policy. If we are going to take that 
approach, it jeopardizes the use of many things, whether 
they be for humans or animals. 
0. Radostits: I was going to ask the same question, 
because it seems to me that sooner or later we will be 
able to demonstrate that a Campylobacter infection in a 
human came from a chicken, from a cow, or from a 
horse. It has to happen sooner or later. It seems to 
me that decisions are being made based on one, two or 
three cases. If it happens once, it is going to become 
an avalanche, and regardless of what this group says, 
or any other group says, in the end what matters is what 
the FDA says. How can we go to the FDA and point 
out that decisions should not be made based on one or 
two cases? 
T. Cox: I have heard the CVM say in a public meeting 
that it is concerned about the avalanche theory, which is 
why we may not be seeing much now. However, I think 
that, because of the way in which they do their 
attributable risk calculations, they think that there is a 
big effect right now. There are 11 000 people with excess 
days of diarrhea that could be prevented. I think that 
this is based on a miscalculation, but that the CVM is 
concerned that this is the tip of the iceberg. I have heard 
many people around this table ask whether it is a good 
idea to remove enrofloxacin, and whether anyone thinks 
that it would prevent a detectable number of human 
illnesses; and I haven’t heard anyone say that they are 
sure that this is true. I feel that if we had the CVM with 
US today, we might possibly hear a different response.The 
CVM thinks that the data show that this is true; my 
understanding is that the CVM partly looks at the trends, 
does not correct those trends for travel, and if it finds 
a trend that is upward, then it decides that maybe some 
fraction of that is attributable to enrofloxacin use. This 
seems to me to be a very confused line of thought, but 
that is where regulatory policies take us. I would like to 
know whether anyone has confidence in the evidence that 
there is a detectable causal link between enrofloxacin use 
in chickens and resistant organisms in people. I would 
even generalize that, and ask what fraction of all 
Campylobacter cases is clearly attributable to chickens 
as opposed to something else, or not attributable at all? 
I know what my data tell me. 
0. Radostits: What kind of evidence do we need to 
support the causal link? 
M. Ginevan: If, in different parts of the country, or 
in different countries, where there are strong seasonal 
fluctuations in chicken-driven campylobacteriosis and 
resistance, it was observed that human populations 
somehow consistently echoed what was going on in the 
chicken population, maybe with some lag time between 
them, that to me would be very impressive evidence; 
however, the seasonality doesn’t work out right as far as 
I can tell. That is one kind of evidence. Another kind of 
evidence might be if international data were examined, 
with correction for travel, there was no increase in 
resistance in human pathogens before enrofloxacin was 
introduced into a country. For example, in 1970, cipro- 
floxacin could be introduced, without an effect on resist- 
ance. In 1980, enrofloxacin could be introduced, and an 
increase in resistance or a consistent pattern could be 
seen. I would suggest that this would be evidence for 
a causal connection. From what I have been able to 
tease out of international data, which is confusingly and 
distressingly sparse, it looks as though trends don’t have 
much to do with when enrofloxacin was introduced into 
different countries. These are possible lines of argument 
that could support a causal connection. I would welcome 
other ideas and suggestions on what are the testable 
consequences of a causal connection. 
D. Newell: We have recently reviewed the seasonality 
data across Europe and the matching data for chickens 
and humans, and, if anything, the data from many 
countries suggest that humans give Campylobacter to 
chickens, not the other way around. This is much more 
consistent with there being some sort of common source 
for both when it comes to seasonal peaks. 
E. Gonder: I think it may be possible to make some 
scientific conjectures, at least that there is a weak link 
between fluoroquinolone resistance in chickens and 
fluoroquinolone resistance in humans. The problem we 
are going to be faced with is the one that I am sure the 
CVM worries about, which is what is an acceptable 
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degree of risk? I haven’t seen much progress on its part 
in trying to decide whether 5000 people with diarrhea 
are worth 300 000 dead chickens and some environ- 
mental damage. I am not sure if the CVM has any idea 
what constitutes an acceptable degree of risk, and 
I think that the chances of it making that decision itself 
are remote, because it is a political decision. Conse- 
quently, while we need the science, we also need to 
move the entire conversation into a different area that 
addresses welfare and environmental concerns as well as 
strictly public health concerns. 
M. Ginevan: When you mention environmental con- 
cerns, are you are referring to the removal of diseased 
carcasses? 
E. Gonder: I am referring to the fact that it takes 2 lb of 
feed to produce 1 lb of chicken. If the chicken dies, that 
feed is wasted. You then have a consequent deposition 
into the environment of nitrogen and phosphorus. We 
also have to consider the other environmental resources 
dedicated to the milling, polling and eventual removal of 
that bird, and the additional crop space that would be 
required to take care of it. 
M. Ginevan: It could also be that there are 10 lo bacteria 
per gram of stool if the dead bird is being buried, and 
source water contamination by all the carcasses of the 
birds that are being buried. 
E. Gonder: Actually, most of them are being rendered. 
T. Cox: Kim Thompson mentioned the idea that what is 
acceptable depends on the cost. Whether what is going 
on now is acceptable is partly a matter of balancing risk 
and cost benefits, but there is also a prior question: is 
there in fact any detectable risk, and is it acceptable? 
From a cause and effect point of view, the more interest- 
ing question is whether there are detectable risks at 
present. Are our chickens making people sick, and are 
they making them sick in a fluoroquinolone-resistant 
way? That is an interesting sub-question. We don’t even 
have to worry about susceptibility until those questions 
can be answered. 
L. Vogel: The hypothesis is that if somebody is 
prescribed a fluoroquinolone as empirical treatment, 
and they have been infected by a fluoroquinolone- 
resistant campylobacter, then the treatment won’t work, 
and there will be 6 extra days of diarrhea. 
T. Cox: In fact, I think that, in the final risk assessment, 
the FDA/CVM didn’t state the number of days of 
diarrhea, but just said that there would be an adverse 
health effect. They didn’t say what that health effect 
would be. 
L. Vogel: They consider being prescribed a fluoroquino- 
lone while carrying a fluoroquinolone-resistant bacterium 
to be a bad outcome in itself, whether or not the bug 
responds to treatment or whether or not there are 
clinical sequelae. 
T. Cox: If there is no evidence that fluoroquinolones 
have much effect on excretion anyway, how can you 
make these assumptions? 
L. Vogel: It appears that the occurrence of a single case 
is not worth any potential benefits, thus unless with- 
drawal has negative consequences, it is desirable. 
T. Cox: To the extent that size homogeneity is destroyed 
and greater variation is introduced into the process, if it 
is true that chickens carry microbial loads to people, 
then almost certainly it is the unusual chicken with the 
high microbial load that counts, not the average chicken 
flowing through the process. To the extent that you take 
action that increases the variability of the processing, 
and, arguably or obviously, banning fluoroquinolones 
would tend to do that, you may actually create an 
adverse effect where there isn’t one now. I think the 
question of what will happen to humans needs to be 
thought out quite carefully. The FDA approach, and I 
think this is what Kim Thompson was getting at with the 
decision analytic context for the risk analysis, is to say 
that we are going to calculate attributable risk, and when 
that proportional attributable risk gets too high, we are 
going to intervene to protect public health; however, the 
FDA never says what would be the consequences of that 
intervention, and whether it will make things worse than 
they already are. 
R. Carnevale: I think that what you will also find is that 
the FDA will say that it is a public health agency, 
so animal health is not an issue. Also, it will say that 
while fecal contamination may create some bacterial 
contamination of carcasses, that is not an FDA issue, but 
a USDA issue, so it is not their problem. 
M. Ginevan: At slaughter facilities, what level of clean- 
liness, surveillance and microbiological assessment is 
carried out, on a routine day-by-day basis? 
E. Gonder: This varies somewhat from plant to plant. 
The government requirements concerning bacterial 
monitoring are really not very well thought out or 
particularly effective. All plants are cleaned from top to 
bottom once a day. For example, chillers are drained, 
completely sanitized, swept down, hosed down, and 
disinfected, and equipment is disassembled. Different 
plants approach bacterial monitoring in different ways. 
The particular one that I am involved with monitors 
chiller water, surface contamination and number of 
bacteria per gram in different products, and does skin 
swabs for Salmonella and E. coli on a fairly regular basis. 
USDA bacterial monitoring or the required bacterial 
monitoring is inadequate. You probably saw the 
Salmonella performance standards on turkeys, where 
the Center for Science in the Public Interest, under the 
Freedom of Information Act request, named the ‘filthy 
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five’ turkey plants. This ranking was based on 55 indi- that may process, say, 70 000 birds a day, and an annual 
vidual bird samples per plant. Thus we have the USDA ranking based on a sample of 56 birds, and the USDA 
releasing information to a consumer group for a plant contending that this is a statistically valid process control. 
